| Number | Percentage |
---|
Interventiona |
Drug | 287 | 59.1 |
Device | 46 | 9.5 |
Vaccine or biological | 86 | 17.7 |
Other | 102 | 21.0 |
Phaseb |
Phase II | 190 | 39.1 |
Phase III | 110 | 22.6 |
Phase IV | 46 | 9.5 |
Not listed | 153 | 31.5 |
Randomization |
Yes | 372 | 76.5 |
No | 114 | 23.5 |
Fundingc, d |
Industry | 216 | 44.4 |
Non-industry | 270 | 55.6 |
Enrollment |
≥ 100 | 280 | 57.6 |
< 100 | 206 | 42.4 |
Location(s) |
US only | 166 | 34.2 |
US and international | 84 | 17.3 |
International only | 236 | 48.6 |
Trial registrye |
ClinicalTrials.gov | 383 | 87.2 |
EU-CTR | 76 | 17.3 |
ISRCTN | 24 | 5.5 |
Other registriesf | 47 | 10.7 |
- aClinical trials may have involved more than one intervention type
- b13 trials were designated as phase II/phase III
- cFunding information was not reported in the publications of 5 trials, all of which were unregistered; these trials were designated as not reporting industry funding
- dIndustry funding includes partial or full support
- e439 trials were registered. Percentages are expressed based on a denominator of 439. 81 trials were registered in multiple registries, hence percentages may not sum to 100
- f“Other registries” includes: Australia New Zealand Clinical Trials Register (ANZCTR), Chinese Clinical Trial Registry (ChiCTR), Clinical Trial Registry of India (CTRI), German Clinical Trials Register (DRKS), Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC-CTI), Netherlands Trial Register (NTR), University Hospital Medical Information Network (UMIN) (a Japanese registry)
- Abbreviations: EU-CTR European Union Clinical Trials Register, ISRCTN International Standard Randomized Controlled Trial Network